Pharvaris Engages Audiences with Upcoming R&D Call on HAE

Author: Ryan Hughes Updated: 05-12-2025 07:01 AM

Pharvaris Announces a Virtual R&D Call on Deucrictibant

Pharvaris (Nasdaq: PHVS), a biopharmaceutical company based in Zug, Switzerland, is poised to host an informative virtual R&D call titled 'Deucrictibant: Beyond HAE Type 1/2.' This event is set to delve into pivotal topics regarding bradykinin-mediated diseases such as hereditary angioedema (HAE). The call will take place at 8:00 a.m. ET/14:00 CET.

What to Expect During the Virtual Event

This engaging session will focus on a variety of aspects concerning bradykinin-mediated angioedema, including the disease's underlying biology and its prevalence. Participants will learn about current treatment options available and the unmet needs that individuals with bradykinin-mediated angioedema continue to face.

Insights into Deucrictibant

Deucrictibant shows promise in addressing these pressing needs, functioning as a potential breakthrough for those afflicted by the disease. The presentation will also outline Pharvaris’ innovative biomarker strategy aimed at effectively identifying those with bradykinin-mediated angioedema and other related conditions.

Meet the Presenters

A distinguished group of experts will lead the discussion, including:

Danny M. Cohn, M.D., Ph.D., renowned in the field of Vascular Medicine from Amsterdam UMC.
Anne Lesage, Ph.D., Chief Early Development Officer at Pharvaris.
Peng Lu, M.D., Ph.D., Chief Medical Officer at Pharvaris.
Berndt Modig, Chief Executive Officer of Pharvaris.

How to Register

Registration for the live webcast is available on the Pharvaris website under the News and Events section. After the live presentation, attendees will have access to an archived replay of the event for at least 30 days, allowing those who missed it to catch up on this important conversation.

About Pharvaris

Pharvaris is committed to developing innovative solutions in the biopharmaceutical space, particularly focusing on treatment options for bradykinin-mediated angioedema. The company aims to replicate the efficacy of injectable treatments while maximizing patient comfort through oral therapies. Currently, Pharvaris is conducting Phase 3 studies to assess the efficacy and safety of deucrictibant, with positive Phase 2 results bolstering their confidence in its potential.

Through their dedication to research, development, and patient care, Pharvaris is paving the way for advancements in treating angioedema and improving the lives of those who suffer from this challenging condition.

Frequently Asked Questions

What is the focus of the R&D call hosted by Pharvaris?

The R&D call will focus on the novel treatment Deucrictibant and its implications for bradykinin-mediated angioedema.

Who are the presenters for the virtual event?

Presenters include experts from Pharvaris and Amsterdam UMC, specializing in vascular medicine and drug development.

How can interested individuals participate in the event?

Individuals can register for the live webcast through the Pharvaris website under the News and Events section.

What does Pharvaris aim to achieve with Deucrictibant?

Pharvaris aims to provide effective treatment options for patients suffering from HAE and other bradykinin-mediated diseases through Deucrictibant.

Will a recording of the event be available after it concludes?

Yes, an archived replay of the webcast will be available for at least 30 days following the event.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.